Trials / Completed
CompletedNCT02987166
HDCRT Plus Pembrolizumab in Advanced Malignancies
A Pilot Study to Assess the Combination of High-Dose Conformal Radiation Therapy (HDCRT) and Pembrolizumab in Modulating Local and Systemic T-cell Responses in Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- James Larner, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a pilot study to evaluate high-dose conformal radiation therapy (HDCRT) administered in combination with pembrolizumab in patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | High-Dose Conformal Radiation Therapy | 24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions 30 Gy in 5 fractions of 6 Gy each for prostate gland |
| DRUG | Pembrolizumab | 200 mg |
Timeline
- Start date
- 2017-03-21
- Primary completion
- 2020-01-13
- Completion
- 2020-02-10
- First posted
- 2016-12-08
- Last updated
- 2020-12-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02987166. Inclusion in this directory is not an endorsement.